Clinical Trials Browser

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT03505320 2026-04-03

ILUSTRO

Phase 2 Active not recruiting

143 enrolled

Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT05533697 2026-04-03

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

361 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT07276373 2026-04-03

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

Phase 1/2 Recruiting

50 enrolled

Tumor-Agnostic

Neoplasms

NCT07476326 2026-04-03

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

Phase 1 Not yet recruiting

120 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms

NCT02693535 2026-04-02

TAPUR

Phase 2 Recruiting

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT03899155 2026-04-01

Pan Tumor Rollover Study

Phase 2 Recruiting

1,500 enrolled

Tumor-Agnostic

Neoplasms

NCT06031233 2026-03-30

MINUTE

Phase 4 Recruiting

776 enrolled

Tumor-Agnostic

Neoplasms

NCT04336241 2026-02-27

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Phase 1 Active not recruiting

36 enrolled

BreastDermatologicGastrointestinalThoracic

Uveal Melanoma, Breast Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasms

NCT03400332 2026-02-24

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Phase 1/2 Completed

281 enrolled 44 charts

Dermatologic

Melanoma, Neoplasms

NCT07192926 2026-02-20

SARCO-CTI

Completed

131 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Neoplasms, Sarcopenia

NCT03388190 2026-02-13

METIMMOX

Phase 2 Completed

80 enrolled 13 charts

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT04078295 2026-02-10

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Phase 1/2 Active not recruiting

125 enrolled

Tumor-Agnostic

Neoplasms

NCT06880549 2026-02-05

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors

Phase 1 Active not recruiting

57 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence

Clinical Trials

HESTIA

ACTengine

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

FOG-001 in Locally Advanced or Metastatic Solid Tumors

ILUSTRO

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

TAPUR

Pan Tumor Rollover Study

MINUTE

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

SARCO-CTI

METIMMOX

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors